Whether or not the new Prescription Drug Pricing Reduction Act is a good policy, if it is enacted, its proposals have to work as intended and ensure compliant operationalization, writes Jeremy Docken.
Jeremy Docken
Advertisement
Articles by Jeremy Docken
A look at the systemic problems resulting from the overlap of MDRP and 340B.
Advertisement
Latest Updated Articles
- Non-compliance Costs Hundreds of Millions in Revenue
Published: November 25th 2019 | Updated:
- PDPRA's Operational Challenges
Published: March 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
FDA Announces New Biosimilar-Targeted Draft Guidance
3
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
4
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer
5
